Related Experiment Video
Updated: Oct 10, 2025
07:04
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.2K
Prime Editing for Inherited Retinal Diseases.
Bruna Lopes da Costa1,2, Sarah R Levi1, Eric Eulau3
1Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY, United States.
Frontiers in Genome Editing
|December 13, 2021
Summary
Prime editing offers a promising new approach for treating inherited retinal diseases (IRDs) by precisely correcting genetic mutations. This advanced genome surgery technique shows potential beyond current gene augmentation therapies for IRDs.
Area of Science:
- Ophthalmology
- Genetics
- Biotechnology
Background:
- Inherited retinal diseases (IRDs) are progressive, hereditary conditions causing vision loss due to genetic mutations.
- Currently, only one gene therapy is FDA-approved for IRDs, highlighting a significant unmet need.
- Existing treatments primarily use gene augmentation, delivering healthy DNA copies, rather than directly correcting mutations.
Purpose of the Study:
- To explore the potential of prime editing (PE) as a novel genome surgery technique for treating IRDs.
- To compare the advantages of PE over existing gene augmentation and CRISPR-based genome editing methods.
Main Methods:
- Review of current IRD treatment landscape, including gene augmentation and CRISPR technology.
- Detailed explanation of prime editing mechanism, highlighting its ability to correct various mutation types without double-strand breaks or donor DNA.
- Discussion of EDIT-101, a CRISPR-based therapy targeting the CEP290 gene mutation.
Main Results:
- Prime editing can correct all twelve transition and transversion mutations, plus small insertions/deletions.
- Unlike traditional CRISPR, PE avoids double-strand breaks and the need for donor DNA, enhancing efficiency.
- While still under development, PE demonstrates significant potential for precise genetic correction in IRDs.
Conclusions:
- Prime editing represents a significant advancement in genome surgery for IRDs.
- PE's precision and efficiency offer a potentially superior alternative to current gene augmentation therapies.
- Further development of PE is crucial to overcome challenges and realize its full therapeutic potential for inherited retinal diseases.
